RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
The present invention provides a compound having the structure:
##STR1## wherein X, Y, and Z are independently H, Cl, Br, F,
OCH.sub.3, I, or an alkyl group having 1 to 6 carbon atoms; and R
is ##STR2## wherein n is 0 to 6, X' and Y' are independently H, Cl,
F, CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, C.sub.4 H.sub.9,
OCH.sub.3, OH, CF.sub.3, OCF.sub.3, NO.sub.2, NH.sub.2,
N(CH.sub.3).sub.2, NHCOCH.sub.3, NCS, NHCOCH.sub.2 Br, or N.sub.3,
and (CH.sub.2).sub.n, if present, may be substituted with OH,
OCH.sub.3, or an alkyl or alkenyl group having 1 to 3 carbon atoms.
The present invention also provides a pharmaceutical composition
comprising the compound above and a pharmaceutically acceptable
carrier. The present invention further provides a method for
treating a disease characterized by a dopamine deficiency which
comprises administering to a subject in need of such treatment an
amount of the pharmaceutical composition above effective to treat
the disease.
